Spectrum Pharmaceuticals Six Abstracts of Clinical Data at ASCO Annual Meeting

Spectrum Pharmaceuticals SPPI, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in oncology and hematology, today announced key presentations of clinical data that included: three ZEVALIN® (ibritumomab tiuxetan)-related poster presentations, and one oral presentation and two poster presentations of clinical data for belinostat at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, from May 31 to June 4, 2013. For more information about the ASCO annual meeting and for a complete list of abstracts, please refer to the conference Web site at http://abstract.asco.org/. The following are the key ZEVALIN and belinostat-related abstracts being presented See full press release